Applications of immunogenomics to cancer

• X. Shirley Liu ^[1] ; Elaine R. Mardis
  1. [1] Dana–Farber Cancer Institute

     Dana–Farber Cancer Institute

     City of Boston, Estados Unidos

     
• Localización: Cell, ISSN 0092-8674, Vol. 168, Nº. 4, 2017 (Ejemplar dedicado a: Cancer, the road ahead), págs. 600-612
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Cancer immunogenomics originally was framed by research supporting the hypothesis that cancer mutations generated novel peptides seen as “non-self” by the immune system. The search for these “neoantigens” has been facilitated by the combination of new sequencing technologies, specialized computational analyses, and HLA binding predictions that evaluate somatic alterations in a cancer genome and interpret their ability to produce an immune-stimulatory peptide. The resulting information can characterize a tumor’s neoantigen load, its cadre of infiltrating immune cell types, the T or B cell receptor repertoire, and direct the design of a personalized therapeutic.